- Conditions
- IgA Nephropathy, Berger Disease
- Interventions
- Atacicept, Placebo to match Atacicept
- Biological · Other
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Brisbane, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- IgA Nephropathy
- Interventions
- OMS721, Vehicle (D5W or saline)
- Biological · Other
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- IgA Nephropathy
- Interventions
- AVB-S6-500
- Drug
- Lead sponsor
- Aravive, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Doral, Florida
- Conditions
- IGA Nephropathy
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 6,286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Interventions
- mycophenolate mofetil (CellCept)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- IgA Glomerulonephritis
- Interventions
- omega-3 fatty acids, prednisone, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Up to 40 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
- Conditions
- Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
- Interventions
- Iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more
- Conditions
- Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
- Interventions
- Not listed
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- IgA Nephropathy
- Interventions
- Telitacicept 160mg, Telitacicept 240mg, Placebo
- Drug
- Lead sponsor
- RemeGen Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
- Conditions
- Immunoglobulin A Nephropathy, Healthy Subjects
- Interventions
- Fish Oil
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
- Interventions
- Drug: Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Los Angeles, California • San Dimas, California + 11 more
- Conditions
- IgA Nephropathy
- Interventions
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Drug · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 5
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Interventions
- VIS649, Placebo
- Biological
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- IgA Nephropathy, Proteinuria
- Interventions
- Acthar 80 unit injection
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- IGA Glomerulonephritis
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Low inflammation diet intervention
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Manhattan Beach, California
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- CCX168
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Francisco, California • Reno, Nevada + 2 more
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more